-Bloomberg
Related Posts
Needham Maintains Buy on OncoCyte, Lowers Price Target to $7
Needham analyst Mike Matson maintains OncoCyte (NASDAQ:OCX) with a Buy and lowers the price target from $8 to $7.
Recap: Protara Therapeutics Q1 Earnings
Protara Therapeutics (NASDAQ:TARA) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:00 AM.
Here's what investors need to know about the announcement.
